RF Acquisition Corp II
No SEC Form 4 filings for $RFAI in the last 30 days.
See all $RFAI insider activity →RF Acquisition Corp II (RFAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 2 rfacquisition2_ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 AMENDMENT TO THE THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF RF ACQUISITION CORP II Dated and effective August 12, 2026 by way of special resolution held at an extraordinary meeting of the shareholde
This article provides an in-depth look at the price history of RF Acquisition Corp II Right (RFAIR) stock, including daily prices, trade data, and corporate actions. It details 52-week key points, new highs, and new lows, offering investors tools for historical data analysis and performance tracking. The content is provided by Barchart.com, which also offers various membership levels for enhanced data access.
Berkley W R Corp significantly increased its stake in RF Acquisition Corp II (RFAI) during Q3, acquiring 183,030 additional shares to total 937,845 shares, now representing 0.6% of its portfolio and valued at $10.07 million. Other institutional investors like Radcliffe Capital, Shaolin Capital, and Magnetar Financial have also initiated new positions, indicating growing interest. Despite increased institutional investment, the blank-check company (SPAC), formed in February 2024, faces negative analyst coverage with an average "Sell" rating.
Over the past 7 days, alphai's AI scored 1 news story mentioning RFAI (RF Acquisition Corp II). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent RFAI coverage spans financial news and corporate actions.
The filing updates the SPAC’s post-deadline wind-up and public-share redemption framework, which can affect liquidation timing expectations and near-term risk pricing.
This article provides an in-depth look at the price history of RF Acquisition Corp II Right (RFAIR) stock, including daily prices, trade data, and corporate actions. It details 52-week key points, new highs, and new lows, offering investors tools for historical data analysis and performance tracking. The content is provided by Barchart.com, which also offers various membership levels for enhanced data access.
Institutional investors, notably Berkley W R Corp, increased their holdings in RF Acquisition Corp II (RFAI), indicating potential confidence in the company's future prospects. However, negative analyst coverage and a bearish sentiment suggest caution.
RFAI may experience slight positive sentiment if US investors view biotech IPOs favorably amid trade tensions.
alphai scores every news story that mentions RFAI with an AI model for sentiment and relevance, and aggregates insider trades from RF Acquisition Corp II's SEC EDGAR Form 4 filings. Figures refresh continuously.
RF Acquisition Corp II (RFAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 2 rfacquisition2_ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 AMENDMENT TO THE THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF RF ACQUISITION CORP II Dated and effective August 12, 2026 by way of special resolution held at an extraordinary meeting of the shareholde
3 min readThis article provides an in-depth look at the price history of RF Acquisition Corp II Right (RFAIR) stock, including daily prices, trade data, and corporate actions. It details 52-week key points, new highs, and new lows, offering investors tools for historical data analysis and performance tracking. The content is provided by Barchart.com, which also offers various membership levels for enhanced data access.
3 min readBerkley W R Corp significantly increased its stake in RF Acquisition Corp II (RFAI) during Q3, acquiring 183,030 additional shares to total 937,845 shares, now representing 0.6% of its portfolio and valued at $10.07 million. Other institutional investors like Radcliffe Capital, Shaolin Capital, and Magnetar Financial have also initiated new positions, indicating growing interest. Despite increased institutional investment, the blank-check company (SPAC), formed in February 2024, faces negative analyst coverage with an average "Sell" rating.
4 min readNanyang Biologics, a Singapore-based artificial intelligence drug discovery start-up, plans to list on the Nasdaq stock exchange in the first quarter of 2026 via a merger with a US-listed special-purpose acquisition company (SPAC), as US President Donald Trump vowed to impose hefty tariffs on ...
4 min read
